

The demand must be filed directly with the competent International Preliminary Examining Authority or, if two or more Authorities are competent, with the one chosen by the applicant. The full name or two-letter code of that Authority may be indicated by the applicant on the line below:

IPEA/ AT

# PCT

## CHAPTER II

### DEMAND

under Article 31 of the Patent Cooperation Treaty:  
The undersigned requests that the international application specified below be the subject of international preliminary examination according to the Patent Cooperation Treaty.

For International Preliminary Examining Authority use only	
Identification of IPEA	Date of receipt of DEMAND
<b>Box No. I IDENTIFICATION OF THE INTERNATIONAL APPLICATION</b> Applicant's or agent's file reference MTX_102	
International application No. PCT/IN 03/00294	International filing date (day/month/year) 2 September 2003 (02.09.03)
(Earliest) Priority date (day/month/year) 2 September 2002 (02.09.02)	
Title of invention PHARMACEUTICAL COMPOSITION OF METAXALONE WITH ENHANCED ORAL BIOAVAILABILITY	
<b>Box No. II APPLICANT(S)</b>	
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) SUN PHARMACEUTICAL INDUSTRIES LIMITED ACME PLAZA, ANDHERI-KURLA ROAD, ANDHERI (EAST), MUMBAI 400059	
Telephone No. 91 22 28230102	
Facsimile No. 91 22 28212010	
Teleprinter No.	
Applicant's registration No. with the Office	
State (that is, country) of nationality: IN	State (that is, country) of residence: IN
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) DHARMADHIKARI, NITIN BHALACHANDRA SUN PHARMACEUTICAL ADVANCED RESEARCH CENTER LIMITED, BOMBAY COLLEGE OF PHARMACY BUILDING, 2ND FLOOR, C.S.T. ROAD, KALINA, SANTACRUZ (EAST). MUMBAI 400098	
State (that is, country) of nationality: IN	State (that is, country) of residence: IN
Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.) MUNGRE, ASHISH PRABHAKAR SUN PHARMACEUTICAL ADVANCED RESEARCH CENTER LIMITED, BOMBAY COLLEGE OF PHARMACY BUILDING, 2ND FLOOR, C.S.T. ROAD, KALINA, SANTACRUZ (EAST). MUMBAI 400098	
State (that is, country) of nationality: IN	State (that is, country) of residence: IN
<input checked="" type="checkbox"/> Further applicants are indicated on a continuation sheet.	

## Continuation of Box No. II APPLICANT(S)

If none of the following sub-boxes is used, this sheet should not be included in the demand.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

ZALA, YASHORAJ RUPSIH  
SUN PHARMACEUTICAL ADVANCED RESEARCH CENTER LIMITED,  
BOMBAY COLLEGE OF PHARMACY BUILDING, 2ND FLOOR,  
C.S.T. ROAD, KALINA, SANTACRUZ (EAST). MUMBAI 400098

State (that is, country) of nationality:  
IN

State (that is, country) of residence:  
IN

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

State (that is, country) of nationality:

State (that is, country) of residence:

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

State (that is, country) of nationality:

State (that is, country) of residence:

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

State (that is, country) of nationality:

State (that is, country) of residence:

☐

Further applicants are indicated on another continuation sheet.

**Box No. III AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE**The following person is ☐ agent ☐ common representativeand ☐ has been appointed earlier and represents the applicant(s) also for international preliminary examination.☐ is hereby appointed and any earlier appointment of (an) agent(s)/common representative is hereby revoked.☐ is hereby appointed, specifically for the procedure before the International Preliminary Examining Authority, in addition to the agent(s)/common representative appointed earlier.Name and address: *(Faintly name followed by given name; for a legal entity, full official designation.  
The address must include postal code and name of country.)*SHRIVASTAVA RATNESH  
SUN PHARMACEUTICAL INDUSTRIES LIMITED  
ACME PLAZA, ANDHERI-KURLA ROAD,  
ANDHERI (EAST), MUMBAI 400059

Telephone No.

91 22 28230102

Facsimile No.

91 22 28212010

Teleprinter No.

Agent's registration No. with the Office

☒ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.**Box No. IV BASIS FOR INTERNATIONAL PRELIMINARY EXAMINATION****Statement concerning amendments:\***

1. The applicant wishes the international preliminary examination to start on the basis of:

☒ the international application as originally filedthe description ☒ as originally filed  
☐ as amended under Article 34the claims ☒ as originally filed  
☐ as amended under Article 19 (together with any accompanying statement)  
☐ as amended under Article 34the drawings ☒ as originally filed  
☐ as amended under Article 342. ☐ The applicant wishes any amendment to the claims under Article 19 to be considered as reversed.3. ☒ The applicant wishes the start of the international preliminary examination to be postponed until the expiration of the applicable time limit under Rule 69.1(d).4. ☐ The applicant expressly wishes the international preliminary examination to start earlier than at the expiration of the applicable time limit under Rule 54bis.1(a).

\* Where no check-box is marked, international preliminary examination will start on the basis of the international application as originally filed or, where a copy of amendments to the claims under Article 19 and/or amendments of the international application under Article 34 are received by the International Preliminary Examining Authority before it has begun to draw up a written opinion or the international preliminary examination report, as so amended.

Language for the purposes of international preliminary examination: **ENGLISH**☒ which is the language in which the international application was filed.☐ which is the language of a translation furnished for the purposes of international search.☐ which is the language of publication of the international application.☐ which is the language of the translation (to be) furnished for the purposes of international preliminary examination.**Box No. V ELECTION OF STATES**

The filing of this demand constitutes the election of all Contracting States which are designated and are bound by Chapter II of the PCT.

## Box No. VI CHECK LIST

The demand is accompanied by the following elements, in the language referred to in Box No. IV, for the purposes of international preliminary examination:

- |  |   |          |
|--|---|----------|
| 1. translation of international application                              | : | sheets   |
| 2. amendments under Article 34   | : | sheets   |
| 3. copy (or, where required; translation) of amendments under Article 19 | : | sheets   |
| 4. copy (or, where required; translation) of statement under Article 19  | : | sheets   |
| 5. letter  | : | 1 sheets |
| 6. other (specify)   | : | sheets   |

For International Preliminary  
Examining Authority use only

received	not received
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>


The demand is also accompanied by the item(s) marked below:

- |  |  |
|--|--|
| 1. <input checked="" type="checkbox"/> fee calculation sheet                             | 5. <input type="checkbox"/> statement explaining lack of signature                         |
| 2. <input type="checkbox"/> original separate power of attorney                          | 6. <input type="checkbox"/> sequence listing in computer readable form                     |
| 3. <input type="checkbox"/> original general power of attorney                           | 7. <input type="checkbox"/> tables in computer readable form related to a sequence listing |
| 4. <input type="checkbox"/> copy of general power of attorney; reference number, if any: | 8. <input type="checkbox"/> other (specify):   |

## Box No. VII SIGNATURE OF APPLICANT, AGENT OR COMMON REPRESENTATIVE

Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the demand).

MR DILIP SHANTILAL SHANGHVI  
CHAIRMAN AND MANAGING DIRECTOR,  
SUN PHARMACEUTICAL INDUSTRIES LIMITED.



## For International Preliminary Examining Authority use only

1. Date of actual receipt of DEMAND:

2. Adjusted date of receipt of demand due to CORRECTIONS under Rule 60.1(b):

3. ☐ The date of receipt of the demand is AFTER the expiration of 19 months from the priority date and item 4 or 5, below, does not apply.
- ☐ The applicant has been informed accordingly.
4. ☐ The date of receipt of the demand is WITHIN the time limit of 19 months from the priority date as extended by virtue of Rule 80.5.
5. ☐ Although the date of receipt of the demand is after the expiration of 19 months from the priority date, the delay in arrival is EXCUSED pursuant to Rule 82.

6. ☐ The date of receipt of the demand is AFTER the expiration of the time limit under Rule 54bis.1(a) and item 7 or 8, below, does not apply.
7. ☐ The date of receipt of the demand is WITHIN the time limit under Rule 54bis.1(a) as extended by virtue of Rule 80.5.
8. ☐ Although the date of receipt of the demand is after the expiration of the time limit under Rule 54bis.1(a), the delay in arrival is EXCUSED pursuant to Rule 82.

## For International Bureau use only

Demand received from IPEA on: